摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-3,4-二氢-2H-异喹啉-1-酮 | 147497-32-3

中文名称
6-溴-3,4-二氢-2H-异喹啉-1-酮
中文别名
6-溴-3,4-二氢异喹啉-1(2H)-酮
英文名称
6-bromo-3,4-dihydroisoquinolin-1(2H)-one
英文别名
6-bromo-3,4-dihydro-2H-isoquinolin-1-one;6-bromo-1-oxo-1,2,3,4-tetrahydroisoquinoline
6-溴-3,4-二氢-2H-异喹啉-1-酮化学式
CAS
147497-32-3
化学式
C9H8BrNO
mdl
——
分子量
226.073
InChiKey
FQPKKECSRKYXIZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    170.0-173.1 °C
  • 沸点:
    453.3±45.0 °C(Predicted)
  • 密度:
    1.559±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933790090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:708722d2225736a380ad148ec87b8713
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 6-Bromo-3,4-dihydro-2h-isoquinolin-1-one
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-3,4-dihydro-2h-isoquinolin-1-one
CAS number: 147497-32-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8BrNO
Molecular weight: 226.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

6-溴-3,4-二氢-2H-异喹啉-1-酮可作为医药合成中的重要中间体。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5

反应信息

  • 作为反应物:
    参考文献:
    名称:
    2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one Derivatives as Potent and Selective Histamine-3 Receptor Antagonists
    摘要:
    On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a new class of 2-(pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives (3-50) were synthesized and evaluated as potent H-3 receptor antagonists. In particular, compound 39 exhibited potent in vitro binding and functional activities at the H-3 receptor, good selectivities against other neurotransmitter receptors and ion channels, acceptable pharmacokinetic properties, and a favorable in vivo profile.
    DOI:
    10.1021/jm300011d
  • 作为产物:
    描述:
    5-溴茚酮 在 sodium azide 、 甲烷磺酸 作用下, 以 甲苯 为溶剂, 以39%的产率得到6-溴-3,4-二氢-2H-异喹啉-1-酮
    参考文献:
    名称:
    Deoxyhypusine Synthase 的新系列强效变构抑制剂
    摘要:
    脱氧hypusine 合酶(DHPS) 是负责hypusine 修饰的主要酶,从而激活真核翻译起始因子5A (eIF5A),这是调节与肿瘤增殖相关的蛋白质翻译过程的关键。尽管 DHPS 抑制剂可能是治疗癌症的一种有前景的治疗选择,但只有少数研究报告了具有这种抑制特性的类药物化合物。因此,在这项工作中,我们设计并合成了一个具有稠环支架的新化学系列,这些化合物是由高通量筛选命中化合物设计的,发现了一种具有有效抑制活性的 5,6-二氢噻吩并 [2,3- c ] 吡啶衍生物 ( 26d ) ; 此外,具有26d的 DHPS 复合物的 X 射线晶体学分析与先前报道的抑制剂相比,表现出独特的变构结合模式。这些发现对于 DHPS 构象变化的功能分析以及变构抑制剂的基于结构的设计可能非常有用。
    DOI:
    10.1021/acsmedchemlett.0c00331
点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILES COMME INHIBITEURS DE FAAH
    申请人:MERCK & CO INC
    公开号:WO2009151991A1
    公开(公告)日:2009-12-17
    The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease
    本发明涉及某些咪唑生物,其可用作脂肪酰胺解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕森病。
  • [EN] OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS D'OXAZOLE UTILES COMME INHIBITEURS DE FAAH
    申请人:MERCK & CO INC
    公开号:WO2010017079A1
    公开(公告)日:2010-02-11
    The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
    本发明涉及某些噁唑生物,其可用作脂肪酸酰胺解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕森病。
  • Discovery of 3,4-Dihydrobenzo[<i>f</i>][1,4]oxazepin-5(2<i>H</i>)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects
    作者:Yueshan Li、Liting Zhang、Ruicheng Yang、Zeen Qiao、Ming Wu、Chong Huang、Chenyu Tian、Xinling Luo、Wei Yang、Yun Zhang、Linli Li、Shengyong Yang
    DOI:10.1021/acs.jmedchem.1c00672
    日期:2022.2.10
    colorectal cancer (CRC) that is often associated with dysregulation of Wnt/β-catenin signaling pathway. Herein, we report the discovery of a series of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of TNIK inhibitors. Structure–activity relationship (SAR) analyses led to the identification of a number of potent TNIK inhibitors with compound 21k being the most active one (IC50:
    Traf2 和 Nck 相互作用蛋白激酶 (TNIK) 是 Wnt/β-catenin 通路的下游信号蛋白,被认为是治疗结直肠癌 (CRC) 的潜在靶点,结直肠癌通常与Wnt/β-连环蛋白信号通路。在此,我们报告发现了一系列 3,4-二氢苯并[ f ][1,4]oxazep​​in-5(2 H )-one 衍生物作为一类新型 TNIK 抑制剂。构效关系 (SAR) 分析鉴定出许多有效的 TNIK 抑制剂,其中化合物21k是最活跃的一种 (IC 50 : 0.026 ± 0.008 μM)。该化合物还对 TNIK 对 406 种其他激酶表现出优异的选择性。在体外试验中,化合物21k可以有效抑制 CRC 细胞增殖和迁移,并在 HCT116 异种移植小鼠模型中表现出相当大的抗肿瘤活性。它还显示出良好的药代动力学特性。总体而言, 21k可能是针对 TNIK 药物发现的有前途的先导化合物,值得进一步研究。
  • TYK2 INHIBITORS AND USES THEREOF
    申请人:Nimbus Lakshmi, Inc.
    公开号:US20160251376A1
    公开(公告)日:2016-09-01
    The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。
  • ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS
    申请人:Zhou Dahui
    公开号:US20090069300A1
    公开(公告)日:2009-03-12
    The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.
    本发明提供了一种公式I的化合物及其用于治疗与组胺-3受体相关或受其影响的中枢神经系统疾病的应用。
查看更多